Predictors of recurrence following laparoscopic radical hysterectomy for early-stage cervical cancer: A multi-institutional study.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
10 2020
Historique:
received: 08 05 2020
accepted: 28 06 2020
pubmed: 16 7 2020
medline: 15 4 2021
entrez: 16 7 2020
Statut: ppublish

Résumé

To assess predictors of recurrence following laparoscopic radical hysterectomy (LRH) for apparent early stage cervical cancer (CC). This is a retrospective multi-institutional study reviewing data of consecutive patients who underwent LRH for FIGO 2009 stage IA1 (with lymphovascular space invasion (LVSI)), IA2 and IB1(≤4 cm) CC, between January 2006 and December 2017. The following histotypes were included: squamous, adenosquamous, and adenocarcinoma. Multivariable models were used to estimate adjusted odds ratio (OR) and corresponding 95% CI. Factors influencing disease-free survival (DFS) and disease-specific survival (DSS) were also explored. 428 patients were included in the analysis. With a median follow-up of 56 months (1-162) 54 patients recurred (12.6%). At multivariable analysis, tumor size (OR:1.04, 95%CI:1.01-1.09, p = .02), and presence of cervical residual tumor at final pathology (OR: 5.29, 95%CI:1.34-20.76, p = .02) were found as predictors of recurrence; conversely preoperative conization reduced the risk (OR:0.32, 95%CI:0.11-0.90, p = .03). These predictors remained significant also in the IB1 subgroup: tumor size: OR:1.05, 95%CI:1.01-1.09, p = .01; residual tumor at final pathology: OR: 6.26, 95%CI:1.58-24.83, p = .01; preoperative conization: OR:0.33, 95%CI:0.12-0.95, p = .04. Preoperative conization (HR: 0.29, 95%CI: 0.13-0.91; p = .03) and the presence of residual tumor on the cervix at the time of surgery (HR: 8.89; 95%CI: 1.39-17.23; p = .01) independently correlated with DFS. No independent factors were associated with DSS. In women with early stage CC the presence of high-volume disease at time of surgery represent an independent predictor of recurrence after LRH. Conversely, preoperative conization and the absence of residual disease at the time of surgery might play a protective role.

Identifiants

pubmed: 32665147
pii: S0090-8258(20)32334-9
doi: 10.1016/j.ygyno.2020.06.508
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

164-170

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All authors do not have any personal or financial conflict of interest to declare.

Auteurs

J Casarin (J)

Obstetrics and Gynecology Department of the University of Insubria, Varese, Italy. Electronic address: j.casarin@uninsubria.it.

A Buda (A)

Department of Obstetrics and Gynecology, Azienda Ospedaliera San Gerardo, University of Milano-Bicocca, Monza, Italy.

G Bogani (G)

Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.

F Fanfani (F)

Dipartimento Scienze della vita e sanità pubblica, Università Cattolica del Sacro Cuore, Rome, Italy; Dipartimento della salute della donna, del bambino e di sanità pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

A Papadia (A)

Department of Obstetrics and Gynecology, University Hospital of Bern and University of Bern, Bern, Switzerland; Department of Gynecology and Obstetrics, University of the Italian Switzerland (USI), Ente Ospedaliero Cantonale of Lugano, Lugano, Switzerland.

M Ceccaroni (M)

Department of Obstetrics and Gynecology, Gynecology Oncology and Minimally Invasive Pelvic Surgery, IRCCS Ospedale Sacro Cuore - Don Calabria, Negrar, Verona, Italy.

M Malzoni (M)

Endoscopica Malzoni, Center for Advanced Endoscopic Gynecologic Surgery, Avellino, Italy.

A Pellegrino (A)

Department of Obstetrics and Gynaecology, Ospedale Alessandro Manzoni, Lecco, Italy.

F Ferrari (F)

Department of Obstetrics and Gynecology, Spedali Civili of Brescia, Brescia, Italy.

S Greggi (S)

Department of Gynecologic Oncology, Istituto Nazionale Tumori, IRCCS, "Fondazione G. Pascale", Naples, Italy.

S Uccella (S)

Departments of Obstetrics and Gynecology, Ospedale degli Infermi, Biella, Italy.

C Pinelli (C)

Obstetrics and Gynecology Department of the University of Insubria, Varese, Italy.

A Cromi (A)

Obstetrics and Gynecology Department of the University of Insubria, Varese, Italy.

A Ditto (A)

Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.

G Di Martino (G)

Department of Obstetrics and Gynecology, Azienda Ospedaliera San Gerardo, University of Milano-Bicocca, Monza, Italy.

L Pedone Anchora (LP)

Dipartimento Scienze della vita e sanità pubblica, Università Cattolica del Sacro Cuore, Rome, Italy.

F Falcone (F)

Endoscopica Malzoni, Center for Advanced Endoscopic Gynecologic Surgery, Avellino, Italy; Department of Gynecologic Oncology, Istituto Nazionale Tumori, IRCCS, "Fondazione G. Pascale", Naples, Italy.

F Bonfiglio (F)

Department of Biomedicine, University of Basel, Basel, Switzerland.

F Odicino (F)

Department of Obstetrics and Gynecology, Spedali Civili of Brescia, Brescia, Italy.

M Mueller (M)

Department of Obstetrics and Gynecology, University Hospital of Bern and University of Bern, Bern, Switzerland.

G Scambia (G)

Dipartimento Scienze della vita e sanità pubblica, Università Cattolica del Sacro Cuore, Rome, Italy; Dipartimento della salute della donna, del bambino e di sanità pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

F Raspagliesi (F)

Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.

F Landoni (F)

Department of Obstetrics and Gynecology, Azienda Ospedaliera San Gerardo, University of Milano-Bicocca, Monza, Italy.

F Ghezzi (F)

Obstetrics and Gynecology Department of the University of Insubria, Varese, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH